Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02376036 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of MGD010 in Healthy Subjects
A Phase 1 study of Healthy Subjects, sponsored by MacroGenics.
- Completed
- Registry status
- Phase 1
- Development phase
- 73
- Enrollment target
- 1
- Study location
NCT02376036: Completed Phase 1 study of Healthy Subjects, sponsored by MacroGenics.
NCT02376036 is a Phase 1 study of Healthy Subjects that has completed, run by MacroGenics. The registered enrollment target is 73 participants, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02376036, a Phase 1 study of Healthy Subjects, has completed, sponsored by MacroGenics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 73 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary goal of this Phase 1 study is to assess the safety and tolerability of one MGD010 intravenous (IV) infusion in healthy adult volunteers.
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL Hepatitis A vaccine
- DRUG MGD010
Study Locations (1)
Maryland
- PAREXEL Baltimore Early Phase Clinical Unit - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2015-02 |
| Est. Completion | 2017-02 |
| Phase | Phase 1 |
What the finished NCT02376036 record still lists
NCT02376036 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 73 participants, a relatively small participant target, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (43% lower).
The record links to 1 condition, with Healthy Subjects appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02376036 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT02376036 about?
NCT02376036 is a clinical study titled "Phase 1 Study of MGD010 in Healthy Subjects". The primary goal of this Phase 1 study is to assess the safety and tolerability of one MGD010 intravenous (IV) infusion in healthy adult volunteers.
What is the current status of trial NCT02376036?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 73 participants. The study started on 2015-02. Estimated completion is 2017-02.
What conditions does trial NCT02376036 study?
This clinical trial studies the following conditions: Healthy Subjects.
What interventions are being tested in trial NCT02376036?
The interventions under investigation include: Placebo (DRUG), Hepatitis A vaccine (BIOLOGICAL), MGD010 (DRUG).
Who is sponsoring clinical trial NCT02376036?
This trial is sponsored by MacroGenics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02376036 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Subjects
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02376036's enrollment target sits among peer trials
73 17th of 69 higher than 53 of 69 other Healthy Subjects trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Subjects trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I Study of ICP-332 in Healthy Subjects
RECRUITING · Phase 1
-
A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects
RECRUITING · Phase 1
-
Phase 1 Study of Intravaginal KB15A
RECRUITING · Phase 1
-
A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulations
COMPLETED · Phase 1
-
Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol®
COMPLETED · Phase 1
-
A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03661307 · 73 participants · Phase 1
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- NCT05386108 · 73 participants · Phase 1
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- NCT05961592 · 73 participants · Phase 1
R-2487 in Patients With Rheumatoid Arthritis
- NCT06150664 · 73 participants · Phase 1
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia